FDA approves Sanofi’s Cablivi for aTTPAcquired Thrombotic Thrombocytopenic Purpura (aTTP), Approvals, Blood Disorders, FDA, FDA/Regulatory, Immunosuppression, Nanobodies, Von Willebrand Factor (VWF)The U.S. FDA approved Cablivi in combination with plasma exchange and immunosuppression for treating acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Read more February 6, 2019/by GlobeNewswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 GlobeNewswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png GlobeNewswire2019-02-06 11:45:362019-02-06 13:23:03FDA approves Sanofi’s Cablivi for aTTP
